Drug Profile

XMT 2056

Alternative Names: XMT-2056

Latest Information Update: 30 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mersana Therapeutics
Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action STING1 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Gastric cancer
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

30 Sep 2025 XMT 2056 is still in phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV) (NCT05514717)
31 Dec 2024 Mersana Therapeutics has patent pending applications in the US
31 Dec 2024 Mersana Therapeutics has patent protection for "compositions of matter and methods of use" and 2041 "compositions of matter"

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com